Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clint T Allen

Showing results (51-60 of 102) with videos related to

Pageof 11
Sort By:
Head & Neck|July 22, 2023
Neoadjuvant chemotherapy enhances tumor-specific T cell immunity in patients with HPV-associated oropharyngeal cancerChristian Samaniego, Jay Friedman, Xinping Yang, et al.
Clinical Case Reports|May 24, 2021
HPV32-related Heck's disease in a chronic graft-versus-host disease patient with long-term successful KTP laser treatment: A rare case reportJoe Truong Nguyen, Clint T Allen, Joshua T Dodge, et al.
Cancer Immunology Research|November 4, 2017
Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell CarcinomaLinda Tran, Clint T Allen, Roy Xiao, et al.
Journal for Immunotherapy of Cancer|June 22, 2018
Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapiesJay Friedman, Megan Morisada, Lillian Sun, et al.
Oncoimmunology|October 6, 2018
WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapyLillian Sun, Ellen Moore, Rose Berman, et al.
Oncotarget|September 17, 2017
Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cellsPaul E Clavijo, Ellen C Moore, Jianhong Chen, et al.
Oncoimmunology|February 6, 2018
PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiationMegan Morisada, Paul E Clavijo, Ellen Moore, et al.
Oncoimmunology|June 15, 2018
Nanocomplex-based <i>TP53</i> gene therapy promotes anti-tumor immunity through TP53- and STING-dependent mechanismsEllen C Moore, Lillian Sun, Paul E Clavijo, et al.
Journal for Immunotherapy of Cancer|December 23, 2022
Exploiting the immunogenic potential of standard of care radiation or cisplatin therapy in preclinical models of HPV-associated malignanciesJoshua T Kowalczyk, Kellsye P Fabian, Michelle R Padget, et al.
Iscience|August 14, 2024
TGF-β neutralization attenuates tumor residency of activated T cells to enhance systemic immunity in miceMagdalena Fay, Cem Sievers, Yvette Robbins, et al.
Pageof 11

Showing results (51-60 of 102) with videos related to

Sort By:
Pageof 11
Head & Neck|July 22, 2023
Neoadjuvant chemotherapy enhances tumor-specific T cell immunity in patients with HPV-associated oropharyngeal cancerChristian Samaniego, Jay Friedman, Xinping Yang, et al.
Clinical Case Reports|May 24, 2021
HPV32-related Heck's disease in a chronic graft-versus-host disease patient with long-term successful KTP laser treatment: A rare case reportJoe Truong Nguyen, Clint T Allen, Joshua T Dodge, et al.
Cancer Immunology Research|November 4, 2017
Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell CarcinomaLinda Tran, Clint T Allen, Roy Xiao, et al.
Journal for Immunotherapy of Cancer|June 22, 2018
Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapiesJay Friedman, Megan Morisada, Lillian Sun, et al.
Oncoimmunology|October 6, 2018
WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapyLillian Sun, Ellen Moore, Rose Berman, et al.
Oncotarget|September 17, 2017
Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cellsPaul E Clavijo, Ellen C Moore, Jianhong Chen, et al.
Oncoimmunology|February 6, 2018
PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiationMegan Morisada, Paul E Clavijo, Ellen Moore, et al.
Oncoimmunology|June 15, 2018
Nanocomplex-based <i>TP53</i> gene therapy promotes anti-tumor immunity through TP53- and STING-dependent mechanismsEllen C Moore, Lillian Sun, Paul E Clavijo, et al.
Journal for Immunotherapy of Cancer|December 23, 2022
Exploiting the immunogenic potential of standard of care radiation or cisplatin therapy in preclinical models of HPV-associated malignanciesJoshua T Kowalczyk, Kellsye P Fabian, Michelle R Padget, et al.
Iscience|August 14, 2024
TGF-β neutralization attenuates tumor residency of activated T cells to enhance systemic immunity in miceMagdalena Fay, Cem Sievers, Yvette Robbins, et al.
Pageof 11